ArticleBrain informatics2025
Advancing Alzheimer's disease detection: a novel convolutional neural network based framework leveraging EEG data and segment length analysis.
Article in Brain informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Evaluating multi-level membership inference risk in federated EEG learning.Brain informatics · 2026Article
- CONECT: Novel Weighted Networks Framework Leveraging Angle-Relation Connection (ARC) and Metaheuristic Algorithms for EEG-Based Dementia Classification.Sensors (Basel, Switzerland) · 2025Article
- Artificial Intelligence-Driven Neuromodulation in Neurodegenerative Disease: Precision in Chaos, Learning in Loss.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder that primarily affects memory, thinking, and behavior, leading to dementia, a severe cognitive decline. While no cure currently exists, recent advancements in preventive drug trials and therapeutic management have increased interest in developing clinical algorithms for early detection and biomarker identification. Electroencephalography (EEG) is noninvasive, cost-effective, and has high temporal resolution, making it a promising tool for automated AD detection. However, conventional machine learning approaches often fall short in accurately detecting AD due to their limited architectures. We also need to investigate the impact of EEG signal segment length on classification accuracy. To address these issues, a deep learning-based framework is proposed to detect AD using EEG data, focusing on determining the optimal segment length for classification. This framework contains EEG data collection, pre-processing for noise removal, temporal segmentation, convolutional neural network (CNN) model training and classification, and finally, evaluation. We have tested different segment lengths to test the impact on AD detection. We have used both 10-fold and leave-one-out cross-validation techniques and obtained accuracy of 97.08% and 96.90%, respectively, on a publicly available dataset from AHEPA General University Hospital of Thessaloniki. We have also tested the generalizability of the proposed model by testing it to detect frontotemporal dementia and obtained better results than existing studies. Furthermore, we have validated our proposed CNN model using several ablation studies and layer-wise extracted feature visualization. This study will establish a pioneering direction for future researchers and technology experts in the field of neurodiseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.